カテゴリ： GlobalData, アメリカ, 企業調査

OncoSec Medical Inc (ONCS)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：OncoSec Medical Inc (ONCS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8210
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：59
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. It is also identifying and developing novel immune-targeting agents for use with the ImmunoPulse platform. The company conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US.

OncoSec Medical Inc (ONCS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoSec Medical Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
OncoSec Medical Enters into Research Agreement with University of California 12
OncoSec Medical Enters into Agreement with Merck 13
Avacta Enters into Research Agreement with OncoSec Medical 14
OncoSec Medical Enters into Agreement with Jounce Therapeutics 15
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 16
OncoSec Medical Enters into Research Agreement with University of Washington 17
Licensing Agreements 18
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 18
Equity Offering 19
OncoSec Medical Raises USD8 Million in First Tranche of Private Placement of Shares 19
OncoSec Medical Raises USD23 Million in Public Offering of Shares 20
OncoSec Medical Plans to Raise up to USD16 Million in Public Offering of Shares 21
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoSec Medical Raises USD7 Million in Private Placement of Shares 23
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 25
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 26
OncoSec Medical Raises USD10 Million in Registered Direct Offering 27
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 28
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 29
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 30
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 31
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 32
OncoSec Medical Completes Public Offering Of Units For US$8 Million 33
OncoSec Medical Inc – Key Competitors 35
OncoSec Medical Inc – Key Employees 36
OncoSec Medical Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 25, 2017: OncoSec Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2017 38
Jun 01, 2017: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017 40
Mar 16, 2017: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017 42
Corporate Communications 43
Jul 16, 2018: OncoSec names Sara M. Bonstein as chief financial officer and chief operating officer 43
Jun 25, 2018: OncoSec added to the Russell Microcap Index 44
Jan 16, 2018: OncoSec Appoints Veteran Biopharma Executive Gregory T. Mayes To Board Of Directors 45
Dec 05, 2017: OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to CSO 46
Nov 07, 2017: OncoSec Appoints Daniel J. O’Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company 47
Sep 07, 2017: OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors 48
Sep 05, 2017: OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors 49
Product Approvals 50
Jun 08, 2017: OncoSec Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Unresectable Metastatic Melanoma 50
Feb 27, 2017: OncoSec Granted FDA Fast Track Designation for ImmunoPulse IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab 51
Clinical Trials 52
Apr 03, 2017: OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting 52
Mar 21, 2017: OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models 53
Feb 23, 2017: OncoSec Announces Positive Phase II Data Demonstrating Company’s ImmunoPulse IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients 54
Feb 08, 2017: OncoSec to Present New Clinical Data from Phase 2 Combination Study at ASCO-SITC Clinical Immuno-Oncology Symposium and Corporate Updates at Two Investment Conferences in February 55
Other Significant Developments 56
Jun 28, 2018: OncoSec provides outlook for second half of 2018 56
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoSec Medical Inc, Deals By Therapy Area, 2012 to YTD 2018 9
OncoSec Medical Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoSec Medical Enters into Research Agreement with University of California 12
OncoSec Medical Enters into Agreement with Merck 13
Avacta Enters into Research Agreement with OncoSec Medical 14
OncoSec Medical Enters into Agreement with Jounce Therapeutics 15
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 16
OncoSec Medical Enters into Research Agreement with University of Washington 17
OncoSec Medical Enters Into Licensing Agreement With USF Research Foundation For Electroporation Intellectual Property 18
OncoSec Medical Raises USD8 Million in First Tranche of Private Placement of Shares 19
OncoSec Medical Raises USD23 Million in Public Offering of Shares 20
OncoSec Medical Plans to Raise up to USD16 Million in Public Offering of Shares 21
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 22
OncoSec Medical Raises USD7 Million in Private Placement of Shares 23
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 25
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 26
OncoSec Medical Raises USD10 Million in Registered Direct Offering 27
OncoSec Medical Raises USD7.5 Million in Private Placement of Shares 28
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 29
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 30
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 31
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 32
OncoSec Medical Completes Public Offering Of Units For US$8 Million 33
OncoSec Medical Inc, Key Competitors 35
OncoSec Medical Inc, Key Employees 36
OncoSec Medical Inc, Other Locations 37

List of Figures
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoSec Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoSec Medical Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[OncoSec Medical Inc (ONCS)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Les Laboratoires Servier SAS：企業の戦略的SWOT分析
    Les Laboratoires Servier SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • ITC Holdings Corp.：企業の発電所・SWOT分析2018
    ITC Holdings Corp. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Mirvac Group：企業のM&A・事業提携・投資動向
    Mirvac Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mirvac Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • GenePOC Inc：医療機器：M&Aディール及び事業提携情報
    Summary GenePOC Inc (GenePOC), a subsidiary of Debiopharm Group, is a medical device company that develops rapid molecular devices for providing targeted therapy. The company offers on-the-spot diagnostic devices for achieving optimal patient management. It offers diagnostic instruments based on a n …
  • Medipines Corp-医療機器分野：企業M&A・提携分析
    Summary MediPines Corp (Medipines) develops and commercializes advanced respiratory measurement and monitoring devices. It focuses on the development of portable and non-invasive devices based on pulse oximetry technology. The company’s lead product candidate, Oxistimulator, is a respiratory depress …
  • Salter Labs-医療機器分野：企業M&A・提携分析
    Summary Salter Labs (Salter) is a medical device company that offers home, HME and acute care products. The company offers products which include swivel connector, whisper and silhouette cannula, visible tubing, petite cannula sensitive grips, static connector and humidifier tubing. It also offers o …
  • Kimberly-Clark Corporation：企業の戦略・SWOT・財務情報
    Kimberly-Clark Corporation - Strategy, SWOT and Corporate Finance Report Summary Kimberly-Clark Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Dialog Group Bhd (DIALOG)：企業の財務・戦略的SWOT分析
    Dialog Group Bhd (DIALOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • NRG Energy Inc (NRG)-エネルギー分野：企業M&A・提携分析
    Summary NRG Energy, Inc. (NRG) is an integrated energy company that produces, sells and delivers energy, and energy products and services. The company generates power using diverse sources such as coal, natural gas, nuclear, oil, wind and solar. It trades wholesale energy, capacity, fuel and related …
  • Patara Pharma Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Patara Pharma Inc (Patara Pharma) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of chronic inflammatory and fibrosis. The company develops anti-inflammatory therapeutics for lung diseases and immune disorders. It conducts clinical trials and in …
  • Larix AS-製薬・医療分野：企業M&A・提携分析
    Summary Larix A/S (Larix) is a contract research organization that offers services related to clinical trials assistance. The company provides services such as statistics, data management, clinical research, pharmacovigilance and data monitoring among others. It offers services across all phases of …
  • Freeport-McMoRan Inc：企業のM&A・事業提携・投資動向
    Freeport-McMoRan Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Freeport-McMoRan Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • NuGEN Technologies Inc-医療機器分野：企業M&A・提携分析
    Summary NuGEN Technologies Inc (NuGEN) is a provider of biological science reagents. The company offers DNA and RNA sample preparation products for use in research and diagnostic applications. Its products include Next-Gen Sequencing applications, which include RNA-Seq, targeted resequencing of DNA …
  • Endo International Plc (ENDP)：企業の財務・戦略的SWOT分析
    Endo International Plc (ENDP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Medison Pharma Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Medison Pharma Ltd (Medison) is a drug company that develops and manufactures medical products. The company's oncology products include vectibix, myocet, aranesp, symphony and coloprint. Its neurology products are avonex, tysabri, fampyra, provigil, stryker, dysport and firdapse. Medison off …
  • Yanmar Co Ltd：企業の戦略的SWOT分析
    Yanmar Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Medicines for Malaria Venture：製薬・医療：M&Aディール及び事業提携情報
    Summary Medicines for Malaria Venture (MMV) is a drug developing company that discovers and delivers new, effective and affordable antimalarial drugs. The center provides products that offers efficacy against drug-resistant strains of plasmodium falciparum, potential for intermittent treatments, saf …
  • SpareBank 1 Nord-Norge：企業の戦略・SWOT・財務分析
    SpareBank 1 Nord-Norge - Strategy, SWOT and Corporate Finance Report Summary SpareBank 1 Nord-Norge - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CDI Corp：企業の戦略的SWOT分析
    CDI Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Sarawak Energy Berhad：企業の戦略的SWOT分析
    Sarawak Energy Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆